文献速递免疫规划传染病防控与疫情报告

2015-2017流感疫苗接种后医保人群吉兰-巴雷综合征监测

Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
PubMed 文献 · Vaccine · 2019-09-09

USPRT发现低强度信号,自身对照风险区间分析未发现接种后1-42天GBS风险增加;8-21天窗口图表确认显示高龄和男性风险升高,高剂量疫苗与标准剂量疫苗存在差异。

要点

  • 两季接种后1-42天未发现GBS风险增加。
  • 8-21天窗口高龄和男性GBS风险升高,与文献一致。
  • 高剂量疫苗与标准剂量疫苗的GBS风险差异属新发现,需进一步验证。

核心结论

  • 两季主要分析均未发现流感疫苗接种后1-42天GBS风险增加,结果令人放心。
  • 8-21天窗口所有季节性疫苗和高剂量疫苗后GBS风险轻度升高,但未超过预期范围,且标准剂量疫苗后无此现象。

研究设计与样本

  • 使用更新序贯概率比检验(USPRT)监测GBS风险信号,季末采用自身对照风险区间(SCRI)分析估计比值比,2015-2016季包含病历确认。
  • 主要风险窗口为接种后1-42天,次要窗口为8-21天,对照窗口为43-84天。

主要发现

  • USPRT在两季均发现低强度GBS信号。
  • SCRI分析未发现两季任何流感疫苗后1-42天GBS风险增加。
  • 2015-2016季8-21天窗口,病历确认显示所有季节性疫苗和高剂量疫苗后归因GBS风险分别为0.87(95%CI:0.16,1.49)和1.68(95%CI:0.69,2.41)例/百万接种者。
  • 2015-2016季8-21天窗口,≥75岁受益者接种所有季节性疫苗和高剂量疫苗后GBS风险升高(OR:2.25;95%CI:1.15,4.39;OR:3.67;95%CI:1.52,8.85),男性接种季节性疫苗和高剂量疫苗后风险升高(OR:2.18;95%CI:1.15,4.15;OR:3.33;95%CI:1.35,8.20)。
  • 2016-2017季8-21天窗口,所有季节性疫苗和高剂量疫苗后归因GBS风险分别为0.87(95%CI:0.03,1.61)和1.11(95%CI:0.00,2.01)例/百万接种者;两季标准剂量疫苗在8-21天窗口均未发现GBS风险增加。

临床怎么用

  • 监测结果支持流感疫苗接种后GBS风险总体较低,可作为接种获益风险评估的参考。
  • 对高龄和男性接种者,尤其使用高剂量疫苗时,应关注GBS相关症状的监测与报告。

局限性

  • 8-21天窗口的风险差异属假设生成性发现,可能源于疫苗因素(如抗原量或毒株)或宿主因素,需进一步研究验证。
  • 2016-2017季未进行病历确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guillain-Barré syndrome (GBS) is a serious acute demyelinating disease, an increased risk of which was found after the 1976 swine flu vaccinations. The U.S. Food and Drug Administration, in collaboration with the Centers for Medicare & Medicaid Services, has been conducting active surveillance for GBS after influenza vaccinations of Medicare Fee-For-Service beneficiaries since 2009. METHODS: We conducted active surveillance for GBS claims in the 2015-2016 and 2016-2017 influenza seasons using the Updating Sequential Probability Ratio Test (USPRT) to monitor for signals of GBS risk. We performed self-controlled risk interval (SCRI) analyses at the end of both seasons, including chart confirmation in the 2015-2016 season, to estimate the odds ratio of GBS risk. We used 1-42 and 8-21 days post-vaccination as primary and secondary risk windows, respectively, and 43-84 days post-vaccination as the control window. RESULTS: Over 13 million beneficiaries were vaccinated in each season. USPRT found a low magnitude signal for GBS in both seasons. SCRI analyses did not find excess GBS risk following any influenza vaccine for days 1-42 post-vaccination in either season. In the 2015-2016 season, for the 8-21 day window, our chart-confirmation showed an attributable GBS risk of 0.87 (95% CI: 0.16, 1.49) and 1.68 (95% CI: 0.69, 2.41) cases per million vaccinees after all seasonal and high dose (HD) vaccines, respectively, an elevated GBS risk for beneficiaries aged ≥75 years following all seasonal vaccines (OR: 2.25; 95% CI: 1.15, 4.39) and HD vaccine (OR: 3.67, 95% CI: 1.52, 8.85), and an elevated GBS risk for males who received seasonal vaccines (OR: 2.18; 95% CI: 1.15, 4.15) and HD vaccine (OR: 3.33; 95% CI: 1.35, 8.20). The finding of elevated GBS risk with advancing age and in males is consistent with literature; however, a distinction between HD and SD was a new finding. In the 2016-17 season, for the 8-21 day window, attributed cases showed an attributable GBS risk of 0.87 (95% CI: 0.03, 1.61) and 1.11 (95% CI: 0.00, 2.01) cases per million vaccinees after all seasonal and HD vaccines, respectively. We found no excess GBS risk for standard dose vaccines in the 8-21 day window in either season. CONCLUSIONS: Our primary analysis finding of no excess GBS risk during both seasons was reassuring. The slightly elevated GBS risk, although in the expected range, in the 8-21 day window after all seasonal and high dose vaccines, but not after standard dose vaccines is hypothesis-generating because the difference may be due to vaccine factors such as antigen amount or strains in various seasons or due to host factors.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arya DP, Said MA, Izurieta HS, et al. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries. Vaccine. 2019. PMID: 31515146. doi:10.1016/j.vaccine.2019.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。